SUPERNUS PHARMACEUTICALS INC's ticker is SUPN and the CUSIP is 868459108. A total of 211 filers reported holding SUPERNUS PHARMACEUTICALS INC in Q3 2020. The put-call ratio across all filers is 3.03 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2021 | $2,610,000 | -9.3% | 99,700 | -12.9% | 0.00% | 0.0% |
| Q4 2020 | $2,879,000 | +19.5% | 114,414 | -1.1% | 0.00% | 0.0% |
| Q3 2020 | $2,410,000 | -8.7% | 115,641 | +4.0% | 0.00% | -33.3% |
| Q2 2020 | $2,641,000 | +31.8% | 111,181 | -0.2% | 0.00% | +50.0% |
| Q1 2020 | $2,004,000 | -44.9% | 111,423 | -27.4% | 0.00% | -33.3% |
| Q4 2019 | $3,638,000 | +28.0% | 153,381 | +48.2% | 0.00% | 0.0% |
| Q3 2019 | $2,843,000 | +13.8% | 103,473 | +37.0% | 0.00% | 0.0% |
| Q2 2019 | $2,499,000 | -9.6% | 75,512 | -4.3% | 0.00% | 0.0% |
| Q1 2019 | $2,765,000 | +10.2% | 78,904 | +4.4% | 0.00% | -25.0% |
| Q4 2018 | $2,510,000 | -38.9% | 75,571 | -7.4% | 0.00% | -20.0% |
| Q3 2018 | $4,107,000 | -5.4% | 81,571 | +12.4% | 0.01% | -16.7% |
| Q2 2018 | $4,343,000 | +82.2% | 72,557 | +39.4% | 0.01% | +100.0% |
| Q1 2018 | $2,384,000 | +1.1% | 52,061 | -12.0% | 0.00% | 0.0% |
| Q4 2017 | $2,358,000 | +25.2% | 59,169 | +25.7% | 0.00% | 0.0% |
| Q3 2017 | $1,884,000 | +12.3% | 47,090 | +21.1% | 0.00% | 0.0% |
| Q2 2017 | $1,677,000 | +37.7% | 38,900 | 0.0% | 0.00% | +50.0% |
| Q1 2017 | $1,218,000 | +18.8% | 38,900 | -4.2% | 0.00% | 0.0% |
| Q4 2016 | $1,025,000 | +2.1% | 40,600 | 0.0% | 0.00% | 0.0% |
| Q3 2016 | $1,004,000 | -25.8% | 40,600 | -38.9% | 0.00% | 0.0% |
| Q2 2016 | $1,353,000 | +33.0% | 66,400 | -0.4% | 0.00% | 0.0% |
| Q1 2016 | $1,017,000 | -4.7% | 66,700 | -16.0% | 0.00% | 0.0% |
| Q4 2015 | $1,067,000 | -29.8% | 79,400 | -26.8% | 0.00% | -33.3% |
| Q3 2015 | $1,521,000 | -2.6% | 108,400 | +17.8% | 0.00% | +50.0% |
| Q2 2015 | $1,562,000 | +267.5% | 92,000 | +86.6% | 0.00% | +100.0% |
| Q1 2015 | $425,000 | 0.0% | 49,300 | 0.0% | 0.00% | 0.0% |
| Q4 2014 | $425,000 | -0.7% | 49,300 | 0.0% | 0.00% | 0.0% |
| Q3 2014 | $428,000 | -20.7% | 49,300 | 0.0% | 0.00% | 0.0% |
| Q2 2014 | $540,000 | +25.0% | 49,300 | 0.0% | 0.00% | 0.0% |
| Q1 2014 | $432,000 | +43100.0% | 49,300 | +49200.0% | 0.00% | – |
| Q3 2013 | $1,000 | 0.0% | 100 | 0.0% | 0.00% | – |
| Q2 2013 | $1,000 | – | 100 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ASHFORD CAPITAL MANAGEMENT INC | 921,962 | $33,402,683 | 5.00% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 423,500 | $15,326,465 | 4.28% |
| ARMISTICE CAPITAL, LLC | 4,350,000 | $157,600,500 | 2.27% |
| S&T BANK/PA | 223,775 | $8,107 | 1.46% |
| Aristotle Capital Boston, LLC | 1,155,149 | $41,851,071 | 1.29% |
| Tributary Capital Management, LLC | 353,671 | $12,813,500 | 1.19% |
| Bridge City Capital, LLC | 62,790 | $2,274,882 | 1.14% |
| RICE HALL JAMES & ASSOCIATES, LLC | 551,285 | $19,973,056 | 1.14% |
| Intrinsic Edge Capital Management LLC | 289,704 | $10,495,976 | 1.05% |
| Parkman Healthcare Partners LLC | 131,878 | $4,777,940 | 1.04% |